A Double-blind, Placebo-controlled, Randomized Study of Vortioxetine Treatment on Major Depression, Cognition, and Systemic Inflammatory Biomarkers Associated With Depression and Cancer Progression in Women With Breast Cancer
Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 05 Oct 2016
At a glance
- Drugs Vortioxetine (Primary)
- Indications Bipolar depression; Breast cancer
- Focus Biomarker; Therapeutic Use
- 29 Sep 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 24 Jun 2016 Planned End Date changed from 1 Jan 2019 to 1 Jul 2019.
- 24 Jun 2016 Planned primary completion date changed from 1 Jan 2018 to 1 Jul 2018.